

37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Drawings:

Please substitute original Figures 1A, 1B, 2, and 3 with substitute Figures 1A, 1B, 2, and 3.

In the Specification

Please substitute the third full paragraph on page 6 (lines 14-18) with the following paragraph:

C1

In certain preferred embodiments, where the cationic lipid compound has a structure according to formula (I), the linker is optionally substituted C₁ to C₁₀ alkyl or alkyloxy, or optionally substituted C₁ to C₁₀ alkenyl or alkenyloxy. In a particularly preferred embodiment, the cationic lipid compound is PentaEG-bis-DMRIE, the chemical structure of which is shown in Figure 1B. The chemical name of PentaEG-bis-DMRIE is penta(ethylene glycol), α , ω -bis-(\pm)-N-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide ether.

47

C